Portfolio company
Modulight Biotherapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
5 investors
Sectors
About
The company develops optogenetic neuromodulation therapies using light-sensitive proteins to treat patients with severe neurological disorders, including chronic pain, epilepsy and movement disorders.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Neuromodulation
This company develops miniaturised peripheral nerve stimulation implants and wireless power systems to treat patients suffering from chronic neuropathic pain.
Neurosciences
This company develops precision sodium channel therapeutics to treat patients with neurological conditions such as genetic epilepsy and chronic neuropathic pain.
Ultra Bionics
The company develops implantable ultrasound technologies to provide neuromodulation and neurological disease therapies for patients with conditions such as Parkinson's and epilepsy.
Neurobioniocs
The company develops flexible bioelectronic fibers that deliver neuromodulation therapy through blood vessels for patients with neurological disorders.
NeuroBionics
This company develops flexible bioelectronic fibers for endovascular neuromodulation to treat neurological and peripheral nerve disorders in patients without requiring invasive open-brain surgery.
Nervonik
This company develops miniaturised peripheral nerve stimulation implants and wireless power systems for patients suffering from chronic neuropathic pain.
Neuroharmonics
This company develops non-invasive ultrasound devices to modulate deep brain circuits for patients with movement disorders, depression, chronic pain, and addiction.
MapLight Therapeutics
This company develops targeted therapeutics for patients with brain disorders including schizophrenia, autism spectrum disorder and Parkinson’s disease.
